MX2007006045A - Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion. - Google Patents

Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion.

Info

Publication number
MX2007006045A
MX2007006045A MX2007006045A MX2007006045A MX2007006045A MX 2007006045 A MX2007006045 A MX 2007006045A MX 2007006045 A MX2007006045 A MX 2007006045A MX 2007006045 A MX2007006045 A MX 2007006045A MX 2007006045 A MX2007006045 A MX 2007006045A
Authority
MX
Mexico
Prior art keywords
depression
treatment
receptor antagonist
drug combination
glucocorticoid receptor
Prior art date
Application number
MX2007006045A
Other languages
English (en)
Inventor
Collin D Ingram
Morag Grassie
Nicol Ferrier
Sasha E Gartside
Allan H Young
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2007006045A publication Critical patent/MX2007006045A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona una combinacion que comprende una cantidad de un SSRI, o una sal o solvato farmaceuticamente aceptable del mismo, y una cantidad de un antagonista de GR, o una sal o solvato farmaceuticamente aceptable del mismo, opcionalmente en asociacion con uno o mas portadores farmaceuticamente aceptables para uso como terapia para la depresion y trastornos relacionados.
MX2007006045A 2004-11-19 2005-11-16 Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion. MX2007006045A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04257199 2004-11-19
PCT/EP2005/056023 WO2006053884A1 (en) 2004-11-19 2005-11-16 Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression

Publications (1)

Publication Number Publication Date
MX2007006045A true MX2007006045A (es) 2007-06-13

Family

ID=34930815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006045A MX2007006045A (es) 2004-11-19 2005-11-16 Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion.

Country Status (10)

Country Link
US (2) US20080255074A1 (es)
EP (2) EP2292269A3 (es)
JP (2) JP5569949B2 (es)
CN (2) CN103316019B (es)
AU (1) AU2005305882B2 (es)
BR (1) BRPI0517847A (es)
CA (1) CA2585317C (es)
IL (1) IL182768A (es)
MX (1) MX2007006045A (es)
WO (1) WO2006053884A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2648930B1 (en) 2010-12-07 2019-11-06 Allison Transmission, Inc. Energy storage system for hybrid electric vehicle

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ATE420649T1 (de) * 2001-10-26 2009-01-15 Organon Nv Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen
US20030162695A1 (en) * 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
BR0314713A (pt) * 2002-09-24 2005-07-26 Combinatorx Inc Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias

Also Published As

Publication number Publication date
IL182768A0 (en) 2007-07-24
US20080255074A1 (en) 2008-10-16
CN101060860A (zh) 2007-10-24
EP2292269A2 (en) 2011-03-09
AU2005305882B2 (en) 2011-07-14
JP5569949B2 (ja) 2014-08-13
EP2292269A3 (en) 2011-08-10
CA2585317A1 (en) 2006-05-26
JP2008520625A (ja) 2008-06-19
CN101060860B (zh) 2013-07-17
US20130231316A1 (en) 2013-09-05
CN103316019B (zh) 2015-10-28
WO2006053884A1 (en) 2006-05-26
BRPI0517847A (pt) 2008-10-21
AU2005305882A1 (en) 2006-05-26
IL182768A (en) 2015-10-29
CA2585317C (en) 2015-02-24
JP2012211145A (ja) 2012-11-01
EP1814589B1 (en) 2015-04-15
CN103316019A (zh) 2013-09-25
EP1814589A1 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
HUP0700335A2 (en) Methods and kits for delivering drugs by nebulisation
ZA200509542B (en) Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
PL1729753T3 (pl) Zastosowanie agonisty receptora NMDA do leczenia szumów usznych powodowanych ekscytotoksycznością ślimaka
UA96414C2 (ru) Комбинация ферохина и производного артемизинина для лечения малярии
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
MX2007003545A (es) Composiciones y metodos para tratar trastornos cognitivos.
HK1155943A1 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
EP2032127A4 (en) TREATMENT OF PSYCHOLOGICAL PATHOLOGIES USING M1 MUSCARINIC RECEPTOR ANTAGONISTS
TW200716561A (en) P38 inhibitors and methods of use thereof
MX2007002606A (es) Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos.
TW200744610A (en) New regimens for controlled drug delivery devices for contraception
UA89773C2 (ru) Фармацевтическая композиция, которая содержащая соль миртазапина
MX2009004113A (es) Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva.
MX2007006045A (es) Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
MXPA05009435A (es) Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
IL177750A0 (en) Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
WO2005094218A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
UA98938C2 (ru) Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights